These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 7536028

  • 1. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA, Alberto P, Hürny C, Bacchi M, Leyvraz S, Thürlimann B, Cerny T, Martinelli G, Stahel R, Ludwig C.
    Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
    [Abstract] [Full Text] [Related]

  • 2. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA, Bacchi M, Hürny C, Bernhard J, Cerny T, Martinelli G, Leyvraz S, Senn HJ, Stahel R, Siegenthaler P.
    Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA, Alberto P, Bleher EA, Ludwig C, Siegenthaler P, Martinelli G, Sauter C, Schatzmann E, Senn HJ.
    Ann Oncol; 1994 Dec; 5(10):921-8. PubMed ID: 7696164
    [Abstract] [Full Text] [Related]

  • 5. [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].
    Navarro M, Mur E, Jolis L, Bellmunt J, Bodi R, Solé LA, Rubio D.
    Rev Clin Esp; 1991 Oct; 189(5):209-12. PubMed ID: 1666192
    [Abstract] [Full Text] [Related]

  • 6. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM.
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [Abstract] [Full Text] [Related]

  • 7. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial.
    Havemann K, Wolf M, Holle R, Gropp C, Drings P, Manke HG, Hans K, Schroeder M, Heim M, Victor N.
    Cancer; 1987 Mar 15; 59(6):1072-82. PubMed ID: 3028596
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 15; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D.
    J Clin Oncol; 1999 Aug 15; 17(8):2300-8. PubMed ID: 10561291
    [Abstract] [Full Text] [Related]

  • 12. Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer.
    Everson LK, Jett JR, O'Fallon JR, Krook JE, Dalton RJ, Mailliard JA, Tschetter LK, Cullinan SA, Gerstner JB, Morton RF.
    Am J Clin Oncol; 1989 Aug 15; 12(4):339-44. PubMed ID: 2547304
    [Abstract] [Full Text] [Related]

  • 13. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Kamei H, Horiguchi T, Kodani T, Maeda T, Tabata M, Shibayama T.
    Cancer; 1993 Sep 01; 72(5):1597-601. PubMed ID: 8394202
    [Abstract] [Full Text] [Related]

  • 14. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R.
    Cancer; 1997 Dec 15; 80(12):2222-9. PubMed ID: 9404698
    [Abstract] [Full Text] [Related]

  • 15. A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification.
    Broder LE, Sridhar KS, Selawry OS, Charyulu KN, Rao RK, Saldana MJ, Donnelly EJ, Raub WA.
    Am J Clin Oncol; 1994 Dec 15; 17(6):527-37. PubMed ID: 7977175
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 17. Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide.
    Jones AL, Holborn J, Ashley S, Smith IE.
    Eur J Cancer; 1991 Dec 15; 27(7):866-70. PubMed ID: 1657078
    [Abstract] [Full Text] [Related]

  • 18. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
    Buccheri G, Ferrigno D, Curcio A, Vola F, Mattalia E.
    Chemioterapia; 1986 Feb 15; 5(1):53-7. PubMed ID: 3955784
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL, Rudd R, Ruiz de Elvira MC, James L, Gower N, Harper PG, Tobias JS, Partridge MR, Davison AG, Trask C.
    J Clin Oncol; 1994 Sep 15; 12(9):1806-13. PubMed ID: 8083704
    [Abstract] [Full Text] [Related]

  • 20. No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancer.
    Eagan RT, Frytak S, Lee RE, Therneau TM, Richardson RL, Creagan ET.
    Am J Clin Oncol; 1987 Apr 15; 10(2):141-5. PubMed ID: 3031976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.